265 related articles for article (PubMed ID: 29339106)
1. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
2. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
4. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
6. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
7. Safinamide: from molecular targets to a new anti-Parkinson drug.
Caccia C; Maj R; Calabresi M; Maestroni S; Faravelli L; Curatolo L; Salvati P; Fariello RG
Neurology; 2006 Oct; 67(7 Suppl 2):S18-23. PubMed ID: 17030736
[TBL] [Abstract][Full Text] [Related]
8. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
11. Safinamide for the treatment of Parkinson's disease.
deSouza RM; Schapira A
Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Cattaneo C; Jost WH; Bonizzoni E
J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
[TBL] [Abstract][Full Text] [Related]
13. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
15. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Alborghetti M; Nicoletti F
Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Müller T; Foley P
Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
[TBL] [Abstract][Full Text] [Related]
17. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
18. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
19. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
20. An expert opinion on safinamide in Parkinson's disease.
Onofrj M; Bonanni L; Thomas A
Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]